Furthermore, studies show that the mAb catumaxomab killed CD133+/EpCAM+ cancer stem cells by attaching to tumour cells and T cells in cases of advanced ovarian cancer with malignant ascites [131]. The gene discussed is EPCAM; the disease is ovarian carcinoma.